Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712943 · ClinicalTrials.gov registry record · Phase 1
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03712943 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 52 participants.
The verdict
NCT03712943, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.
Interventions
- DRUG Nivolumab
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712943
The ClinicalTrials.gov registry entry for NCT03712943 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03712943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712943 about?
NCT03712943 is a clinical study titled "Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer". The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with...
What is the current status of trial NCT03712943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2018-10-23. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT03712943?
The interventions under investigation include: Nivolumab (DRUG), Regorafenib (DRUG).
Who is sponsoring clinical trial NCT03712943?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.